Sensei Biotherapeutics Inc
F:407
Income Statement
Earnings Waterfall
Sensei Biotherapeutics Inc
Income Statement
Sensei Biotherapeutics Inc
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
3
|
2
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(17)
|
(19)
|
(23)
|
(28)
|
(33)
|
(37)
|
(41)
|
(42)
|
(47)
|
(50)
|
(49)
|
(48)
|
(42)
|
(37)
|
(35)
|
(32)
|
(32)
|
(32)
|
(31)
|
(29)
|
(26)
|
|
| Selling, General & Administrative |
(6)
|
(8)
|
(10)
|
(13)
|
(15)
|
(16)
|
(16)
|
(17)
|
(18)
|
(20)
|
(21)
|
(22)
|
(21)
|
(19)
|
(17)
|
(15)
|
(14)
|
(13)
|
(13)
|
(12)
|
(11)
|
|
| Research & Development |
(11)
|
(11)
|
(12)
|
(15)
|
(18)
|
(22)
|
(26)
|
(26)
|
(29)
|
(30)
|
(28)
|
(27)
|
(21)
|
(18)
|
(18)
|
(18)
|
(19)
|
(19)
|
(17)
|
(15)
|
(13)
|
|
| Operating Income |
(17)
N/A
|
(19)
-10%
|
(23)
-25%
|
(28)
-21%
|
(33)
-18%
|
(37)
-13%
|
(41)
-11%
|
(42)
-2%
|
(47)
-10%
|
(50)
-8%
|
(49)
+3%
|
(48)
+1%
|
(42)
+13%
|
(37)
+12%
|
(35)
+6%
|
(32)
+7%
|
(32)
0%
|
(32)
+3%
|
(31)
+2%
|
(29)
+8%
|
(26)
+10%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
(4)
|
(1)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
4
|
3
|
3
|
3
|
3
|
2
|
2
|
2
|
1
|
|
| Non-Reccuring Items |
(1)
|
(1)
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(22)
N/A
|
(20)
+7%
|
(23)
-16%
|
(28)
-21%
|
(33)
-15%
|
(37)
-13%
|
(41)
-12%
|
(42)
-2%
|
(46)
-9%
|
(49)
-6%
|
(46)
+5%
|
(45)
+2%
|
(39)
+14%
|
(34)
+12%
|
(32)
+6%
|
(30)
+7%
|
(30)
0%
|
(30)
-1%
|
(29)
+4%
|
(27)
+8%
|
(24)
+10%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(22)
|
(20)
|
(23)
|
(28)
|
(33)
|
(37)
|
(41)
|
(42)
|
(46)
|
(49)
|
(46)
|
(45)
|
(39)
|
(34)
|
(32)
|
(30)
|
(30)
|
(30)
|
(29)
|
(27)
|
(24)
|
|
| Net Income (Common) |
(23)
N/A
|
(20)
+11%
|
(23)
-16%
|
(28)
-21%
|
(33)
-15%
|
(37)
-13%
|
(41)
-12%
|
(42)
-2%
|
(46)
-9%
|
(49)
-6%
|
(46)
+5%
|
(45)
+2%
|
(39)
+14%
|
(34)
+12%
|
(32)
+6%
|
(30)
+7%
|
(30)
0%
|
(30)
-1%
|
(29)
+4%
|
(27)
+8%
|
(24)
+10%
|
|
| EPS (Diluted) |
-15.38
N/A
|
-13.66
+11%
|
-24.73
-81%
|
-18.46
+25%
|
-21.28
-15%
|
-26.55
-25%
|
-26.91
-1%
|
-27.36
-2%
|
-29.77
-9%
|
-31.65
-6%
|
-30.04
+5%
|
-29.64
+1%
|
-30.5
-3%
|
-24.4
+20%
|
-25.48
-4%
|
-23.63
+7%
|
-23.7
0%
|
-24.01
-1%
|
-23.04
+4%
|
-21.27
+8%
|
-19.13
+10%
|
|